Dr. Jasmohan S. Bajaj, MD
Gastroenterology (Gastroenterology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
VA license 0101243529 · WI license 45285
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 12 payments worth $16,042 in total to this clinician.
| Boehringer Ingelheim International GmbH | $14,732 |
|---|---|
| Spectrum Pharmaceuticals Inc. | $1,310 |
| Consulting Fee | $10,130 |
|---|---|
| Travel and Lodging | $5,771 |
| Food and Beverage | $142 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim International GmbH Nov 5, 2025 | Consulting Fee | $8,085 |
| Boehringer Ingelheim International GmbH Nov 25, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $4,418 |
| Spectrum Pharmaceuticals Inc. Mar 4, 2025 | Consulting Fee ROLVEDON · Oncology | $1,310 |
| Boehringer Ingelheim International GmbH Nov 5, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $1,000 |
| Boehringer Ingelheim International GmbH Nov 12, 2025 | Consulting Fee | $735 |
| Boehringer Ingelheim International GmbH Nov 25, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $216 |
| Boehringer Ingelheim International GmbH Nov 2, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $83.48 |
| Boehringer Ingelheim International GmbH Nov 25, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $53.97 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $507,320 in research payments for these studies, mostly to the institutions running them.
- Multicenter study of outpatients with cirrhosis: NACSELD-III
Sequana Medical US Inc. - Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
Grifols Therapeutics LLC · Terminated · NCT03702920 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Bausch Health US, LLC - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
Sequana Medical US Inc. · Active, not recruiting · NCT03973866 - Multi-center study of outpatients with Cirrhosis: NACSELD-III
Bausch Health US, LLC - Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Grifols Therapeutics LLC · Completed · NCT03451292 - A dose-finding, double-blind, placebo-controlled phase 2 study to eva
GlaxoSmithKline, LLC. - Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Grifols Shared Services North America, Inc. · Active, not recruiting · NCT06052176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.